Lipid-lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel

Nutrition Reviews

Volumn 75, Issue 9, 2017, Pages 731-767

  Cicero, Arrigo F G ^a   Colletti, Alessandro ^a   Bajraktari, Gani ^b,c,d   Descamps, Olivier ^e,f   Djuric, Dragan M ^g,h   Ezhov, Marat ^i,j   Fras, Zlatko ^k,l,m   Katsiki, Niki ⁿ   Langlois, Michel ^f,o   Latkovskis, Gustavs ^p,q   Panagiotakos, Demosthenes B ^r   Paragh, Gyorgy ^s,t   Mikhailidis, Dimitri P ^u   Mitchenko, Olena ^v,w   Paulweber, Bernhard ^x,y   Pella, Daniel ^z,aa   Pitsavos, Christos ^ab,ac   Reiner, Željko ^ad,ae   Ray, Kausik K ^af   Rizzo, Manfredi ^ag,ah   Sahebkar, Amirhossein ^ai   Serban, Maria Corina ^aj   Sperling, Laurence S ^ak   Toth, Peter P ^al,am   Vinereanu, Dragos ^e,an,ao   Vrablík, Michal ^ap,aq   Wong, Nathan D ^ar   Banach, Maciej ^{as,at,au,av,aw}   more..

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY CLINICAL CENTER OF KOSOVO   (Serbia)

^c UNIVERSITY OF PRISHTINA   (Serbia)

^d Kosovo Society of Cardiology   (Serbia)

^e Centres Hospitaliers Jolimont ^*  (Romania)

^f Belgian Atherosclerosis Society   (Belgium)

^g UNIVERSITY OF BELGRADE   (Serbia)

^h Serbian Association for Arteriosclerosis   (Serbia)

ⁱ INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^j Russian National Atherosclerosis Society   (Russian Federation)

^k UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^l UNIVERSITY OF LJUBLJANA   (Slovenia)

^m Slovenian Society of Cardiology   (Slovenia)

ⁿ ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^o General Hospital St Jan   (Belgium)

^p UNIVERSITY OF LATVIA   (Latvia)

^q Baltic Atherosclerosis Society   (Latvia)

^r HAROKOPIO UNIVERSITY   (Greece)

^s UNIVERSITY OF DEBRECEN   (Hungary)

^t Hungarian Atherosclerosis Society   (Hungary)

^u ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^v Ukranian Strazhesko Institute of Cardiology   (Ukraine)

^w Ukrainian Atherosclerosis Society   (Ukraine)

^x PARACELSUS MEDICAL UNIVERSITY   (Austria)

^y Austrian Atherosclerosis Society   (Austria)

^z P J AFÁRIK UNIVERSITY   (Slovakia)

^aa Slovak Association of Atherosclerosis   (Slovakia)

^ab UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^ac Hellenic Atherosclerosis Society   (Greece)

^ad UNIVERSITY OF ZAGREB   (Croatia)

^ae Croatian Atherosclerosis Society   (Croatia)

^af IMPERIAL COLLEGE LONDON   (United Kingdom)

^ag UNIVERSITY OF PALERMO   (Italy)

^ah Euro Mediterranean Institute of Science and Technology   (Italy)

^ai MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^aj University of Medicine and Pharmacy 'Victor Babes'   (Iran)

^ak EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^al JOHNS HOPKINS UNIVERSITY   (United States)

^am CGH MEDICAL CENTER   (United States)

^an CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^ao Romanian Society of Cardiology   (Romania)

^ap CHARLES UNIVERSITY   (Czech Republic)

^aq Czech Atherosclerosis Society   (Czech Republic)

^ar UNIVERSITY OF CALIFORNIA   (United States)

^as MEDICAL UNIVERSITY OF LODZ   (Poland)

^at POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^au UNIVERSITY OF ZIELONA GÓRA   (Poland)

^av Lipid and Blood Pressure Meta Analysis Collaboration Group   (Poland)

^aw Polish Lipid Association   (Poland)

more..

Author keywords

Dyslipidemia; Lipid; Nutraceuticals; Position paper; Recommendations

Indexed keywords

ALPHA TOCOPHEROL; ANTHOCYANIN; ANTILIPEMIC AGENT; BERBERINE; BETA GLUCAN; CARNITINE; CHITOSAN; CHOLESTIN; CONJUGATED LINOLEIC ACID; CURCUMIN; CYNARA ACOLYMUS EXTRACT; GAMMA ORYZANOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISPAGULA; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MANNAN; NUTRACEUTICAL; OMEGA 3 FATTY ACID; PANTETHINE; PHYCOCYANIN; PHYTOSTEROL; POLICOSANOL; PROBIOTIC AGENT; SILYMARIN; SINECATECHINS; SOYBEAN PROTEIN; STANOZOLOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; XUEZHIKANG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOCHEMICAL; TRIACYLGLYCEROL; UNSATURATED FATTY ACID;

ARTICHOKE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHLORELLA; CITRUS BERGANIA; CITRUS FRUIT; CLINICAL PRACTICE; DIETARY FIBER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ECONOMIC ASPECT; ENDOTHELIUM; GARLIC; GLYCYRRHIZA; HEALTH CARE PERSONNEL; HUMAN; INTESTINE ABSORPTION; LIFESTYLE MODIFICATION; LUPIN; MOMORDICA CHARANTIA; NONHUMAN; PATIENT CARE; PHYSICIAN; PREVALENCE; PRIMARY MEDICAL CARE; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SILYBUM MARIANUM; SPIRULINA; BLOOD; DIETARY SUPPLEMENT; DRUG EFFECTS; DRUG INTERACTION; EVIDENCE BASED MEDICINE; LIFESTYLE; LIVER; META ANALYSIS (TOPIC); METABOLISM; OBSERVATIONAL STUDY;

CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; FATTY ACIDS, UNSATURATED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINAL ABSORPTION; LIFE STYLE; LIVER; META-ANALYSIS AS TOPIC; OBSERVATIONAL STUDIES AS TOPIC; PHYTOCHEMICALS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TRIGLYCERIDES;

EID: 85031902306     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1093/nutrit/nux047     Document Type: Article

References (298)

1. World Health Organization. Cardiovascular Diseases (CVDs). 2015. http://www. who.int/mediacentre/factsheets/fs317/en/. Accessed July 28, 2017
2. Perk J, De Backer G, Gohlke H, et al. European Association for Cardiovascular Prevention & Rehabilitation (EACPR); ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635-1701
3. Bloom DE, Cafiero ET, Jané-Llopis E, et al. The Global Economic Burden of Noncommunicable Diseases. Report No.: 080911. Geneva, Switzerland: World Economic Forum; 2011
4. Scottish Intercollegiate Guidelines Network (SIGN). Risk Estimation and the Prevention of Cardiovascular Disease. A National Clinical Guideline. Report No.97 Edinburgh, UK: SIGN; 2007
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421
6. Australian Institute of Health and Welfare. High Blood Cholesterol. Canberra, Australia: Australian Institute of Health and Welfare; 2012-2013
7. Colantonio LD, Bittner V, Reynolds K, et al. Association of serum lipids and coronary heart disease in contemporary observational studies. Circulation. 2016;133:256-264
8. Ford ES, Li C, Pearson WS, et al. Trends in hypercholesterolemia, treatment and control among United States adults. Int J Cardiol. 2010;140:226-235
9. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, et al. American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38-e360
10. Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278
11. Zdrojewski T, Solnica B, Cybulska B, Bandosz P, Rutkowski M, Stokwiszewski J, Gaciong Z, BanachM, Wojtyniak B, PencinaM, Wyrzykowski B. Prevalence of lipid abnormalities in Poland. The NATPOL 2011 survey. Kardiol Pol. 2016;74:213-223
12. Hobbs FD, Banach M, Mikhailidis DP, et al. Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. BMC Med. 2016;14:4. doi:0.1186/s12916-016-0550-5
13. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376:1670-1681
14. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22
15. Shepherd J, Blauw GJ, Murphy MB, et al. PROSPER Study Group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630
16. Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1-full report. J Clin Lipidol. 2015;9:129-169
17. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ. 1994;308:367-372
18. Catapano AL, Graham I, De Backer G, et al. Authors/Task Force Members. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016;253:281-344
19. Reiner Ź. Hypertriglyceridemia and risk of coronary artery disease. Nat Rev Cardiol. 2017;14:401-411
20. Booth JN 3rd, Colantonio LD, Howard G, et al. Healthy lifestyle factors and incident heart disease and mortality in candidates for primary prevention with statin therapy. Int J Cardiol. 2016;207:196-202
21. Banach M, Jankowski P, Jǒžwiak J, et al. PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016. Arch Med Sci. 2017;13:1-45
22. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur J Prev Cardiol. 2016;23:NP1-NP96
23. Vanhees L, Geladas N, Hansen D, et al. on behalf of the writing group. Importance of characteristics and modalities of physical activity and exercise in the management of cardiovascular health in individuals with cardiovascular risk factors: recommendations from the EACPR (part II). Eur J Prev Cardiol. 2012;19:1005-1033
24. Lichtenstein AH, Appel LJ, Brands M, et al. American Heart Association Nutrition Committee. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation. 2006;114:82-96
25. American Heart Association. Lifestyle Changes and Cholesterol. http://www. heart.org/HEARTORG/Conditions/Cholesterol/PreventionTreatmentofHighCholesterol/Lifestyle-Changes-andCholesterol_ UCM_305627_Article.jsp. Accessed March 31, 2017
26. Appel LJ, Sacks FM, Carey VJ, et al. OmniHeart Collaborative Research Group. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA. 2005;294:2455-2464
27. Brown MS, Goldstein JL. Biomedicine. Lowering LDL-not only how low, but how long? Science. 2006;311:1721-1731
28. Brinton EA. Management of hypertriglyceridemia for prevention of atherosclerotic cardiovascular disease. Endocrinol Metab Clin North Am. 2016;45:185-204
29. Patti AM, Toth PP, Giglio RV, et al. Nutraceuticals as an important part of combination therapy in dyslipidaemia. Curr Pharm Des. 2017; Advance access published March 17, doi: 10.2174/1381612823666170317145851
30. Chen ZY, Jiao R, Ma KY. Cholesterol-lowering nutraceuticals and functional foods. J Agric Food Chem. 2008;56:8761-8773
31. Cicero AF, Colletti A. Role of phytochemicals in the management of metabolic syndrome. Phytomedicine. 2016;23:1134-1144
32. Sahebkar A, Serban MC, Gluba-Brzǒzka A, et al. Lipid-modifying effects of nutraceuticals: an evidence-based approach. Nutrition. 2016;32:1179-1192
33. Houston M. The role of nutraceutical supplements in the treatment of dyslipidemia. J Clin Hypertens. 2012;14:121-132
34. Cicero AF, Fogacci F, Colletti A. Food and plant bioactives for reducing cardiometabolic disease risk: an evidence based approach. Food Funct. 2017;8:2076-2088
35. Stroes ES, Thompson PD, Corsini A, et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012-1022
36. Bangalore S, Fayyad R, Hovingh GK, et al. Treating to New Targets Steering Committee and Investigators. Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. Am J Cardiol. 2014;113:2018-2020
37. Reiner Ź. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24:1057-66
38. Banach M, Rizzo M, Toth PP, Farnier M, et al. Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci. 2015;11:1-23
39. Patel J, Martin SS, Banach M. Expert opinion: the therapeutic challenges faced by statin intolerance. Expert Opin Pharmacother. 2016;17:1497-1507
40. Banach M, Serban MC. Discussion around statin discontinuation in older adults and patients with wasting diseases. J Cachexia Sarcopenia Muscle. 2016;7:396-399
41. Banach M, Aronow WS, Serban MC, et al. Lipids, blood pressure and kidney update Lipids Health Dis. 2015;14:167
42. Devaraj S, Jialal I. The role of dietary supplementation with plant sterols and stanols in the prevention of cardiovascular disease. Nutr Rev. 2006;64(7 pt 1):348-354
43. Law M. Plant sterol and stanol margarines and health. Br Med J. 2000;320:861-864
44. Ras RT, Hiemstra H, Lin Y, et al. Consumption of plant sterol-enriched foods and effects on plasma plant sterol concentrations-a meta-analysis of randomized controlled studies. Atherosclerosis. 2013;230:336-346
45. Ferguson JJ, Stojanovski E, MacDonald-Wicks L, et al. Fat type in phytosterol products influence their cholesterol-lowering potential: a systematic review and meta-analysis of RCTs. Prog Lipid Res. 2016;64:16-29
46. Demonty I, Ras RT, van der Knaap HC, et al. The effect of plant sterols on serum triglyceride concentrations is dependent on baseline concentrations: a pooled analysis of 12 randomised controlled trials. Eur J Nutr. 2013;52:153-160
47. Athyros VG, Kakafika AI, Papageorgiou AA, et al. Effect of a plant stanol estercontaining spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors. Nutr Metab Cardiovasc Dis. 2011;21:213-221
48. Talati R, Sobieraj DM, Makanji SS, et al. The comparative efficacy of plant sterols and stanols on serum lipids: a systematic review and meta-analysis. J Am Diet Assoc. 2010;110:719-726
49. Ras RT, Fuchs D, Koppenol WP, et al. The effect of a low-fat spread with added plant sterols on vascular function markers: results of the Investigating Vascular Function Effects of Plant Sterols (INVEST) study. Am J Clin Nutr. 2015;101:733-741
50. Gylling H, Halonen J, Lindholm H, et al. The effects of plant stanol ester consumption on arterial stiffness and endothelial function in adults: a randomised controlled clinical trial. BMC Cardiovasc Disord. 2013;13:50
51. Brown L, Rosner B, Willett WW, et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69:30-42
52. Doi K. Effect of konjac fibre (glucomannan) on glucose and lipids. Eur J Clin Nutr. 1995;49(suppl 3):S190-S197
53. Zhu X, Sun X, Wang M, et al. Quantitative assessment of the effects of betaglucan consumption on serum lipid profile and glucose level in hypercholesterolemic subjects. Nutr Metab Cardiovasc Dis. 2015;25:714-723
54. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on the substantiation of a health claim related to oat beta-glucan and lowering blood cholesterol and reduced risk of (coronary) heart disease pursuant to article 14 of regulation (EC) no 1924/2006. EFSA J. 2010;8:188. doi: 0.2903/j.efsa.2010.1885
55. Reiner Z, Catapano A, De Backer G, et al. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2011;32:1769-1818
56. Cleeman J, Grundy S, Becker D, et al. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults. executive summary of the third report of the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP III). JAMA. 2001;285:2486-2497
57. Tabesh F, Sanei H, Jahangiri M, et al. The effects of beta-glucan rich oat bread on serum nitric oxide and vascular endothelial function in patients with hypercholesterolemia. Biomed Res Int. 2014;2014:481904
58. Anderson JW. Dietary fibre, complex carbohydrate and coronary artery disease. Can J Cardiol. 1995;11(suppl G):55G-62G
59. Wei ZH, Wang H, Chen XY, et al. Time-and dose-dependent effect of psyllium on serum lipids in mild-to-moderate hypercholesterolemia: a meta-analysis of controlled clinical trials. Eur J Clin Nutr. 2009;63:821-827
60. Ribas SA, Cunha DB, Sichieri R, et al. Effects of psyllium on LDL-cholesterol concentrations in Brazilian children and adolescents: a randomised, placebocontrolled, parallel clinical trial. Br J Nutr. 2015;113:134-141
61. Anderson JW, Zettwoch N, Feldman T, et al. Cholesterol-lowering effects of psyllium hydrophilic mucilloid for hypercholesterolemic men. Arch Intern Med. 1988;148:292-296
62. Gibb RD, McRorie JW Jr, Russell DA, et al. Psyllium fiber improves glycemic control proportional to loss of glycemic control: a meta-analysis of data in euglycemic subjects, patients at risk of type 2 diabetes mellitus, and patients being treated for type 2 diabetes mellitus. Am J Clin Nutr. 2015;102:1604-1614
63. Pal S, Khossousi A, Binns C, et al. The effects of 12-week psyllium fibre supplementation or healthy diet on blood pressure and arterial stiffness in overweight and obese individuals. Br J Nutr. 2012;107:725-734
64. Anderson JW, Allgood LD, Lawrence A, et al. Cholesterol-lowering effects of psyllium intake adjunctive to diet therapy in men and women with hypercholesterolemia: meta-analysis of 8 controlled trials. Am J Clin Nutr. 2000;71:472-479
65. Behera SS, Ray RC. Konjac glucomannan, a promising polysaccharide of Amorphophallus konjac K. Koch in health care. Int J Biol Macromol. 2016;92:942-956
66. Sood N, Baker WL, Coleman CI. Effect of glucomannan on plasma lipid and glucose concentrations, body weight, and blood pressure: systematic review and meta-analysis. Am J Clin Nutr. 2008;88:1167-1175
67. Onakpoya I, Posadzki P, Ernst E. The efficacy of glucomannan supplementation in overweight and obesity: a systematic review and meta-analysis of randomized clinical trials. J Am Coll Nutr. 2014;33:70-78
68. Guardamagna O, Abello F, Cagliero P, et al. Could dyslipidemic children benefit from glucomannan intake? Nutrition. 2013;29:1060-1065
69. Martino F, Martino E, Morrone F, et al. Effect of dietary supplementation with glucomannan on plasma total cholesterol and low density lipoprotein cholesterol in hypercholesterolemic children. Nutr Metab Cardiovasc Dis. 2005;15:174-180
70. Martino F, Puddu PE, Pannarale G, et al. Low dose chromium-polynicotinate or policosanol is effective in hypercholesterolemic children only in combination with glucomannan. Atherosclerosis. 2013;228:198-202
71. Baker WL, Tercius A, Anglade M, et al. A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemic patients. Ann Nutr Metab. 2008;55:368-374
72. Rizzo M, Giglio RV, Nikolic D, et al. Effects of chitosan on plasma lipids and lipoproteins: a 4-month prospective pilot study. Angiology. 2014;65:538-542
73. Jull AB, Ni Mhurchu C, Bennett DA, et al. Chitosan for overweight or obesity. Cochrane Database Syst Rev. 2008;(3):CD003892. doi:10.1002/14651858.CD003892.pub3
74. Kim HJ, Ahn HY, Kwak JH, et al. The effects of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes. Food Funct. 2014;10:2662-2669
75. Mhurchu CN, Poppitt S, McGill A, et al. The effect of the dietary supplement, chitosan, on body weight: a randomised controlled trial in 250 overweight and obese adults. Int J Obes. 2004;28:1149-1156
76. Guarner F, Schaafsma GJ. Probiotics. Int J Food Microbiol. 1998;39:237-238
77. Gilliland SE, Nelson CR, Maxwell C. Assimilation of cholesterol by Lactobacillus acidophilus. Appl Environ Microbiol. 1985;49:377-381
78. Mistry P. Natural cholesterol-lowering products: focus on probiotics. Br J Community Nurs. 2014;19(suppl. 11):S14-S18
79. Kim GB, Yi SH, Lee BH. Purification and characterization of three different types of bile salt hydrolases from Bifidobacterium strains. J Dairy Sci. 2004;87:258-266
80. Liong MT, Dunshea FR, Shah NP. Effects of a synbiotic containing Lactobacillus acidophilus ATCC 4962 on plasma lipid profiles and morphology of erythrocytes in hypercholesterolaemic pigs on high-and low-fat diets. Br J Nutr. 2007;98:736-744
81. Cho YA, Kim J. Effect of probiotics on blood lipid concentrations: a meta-analysis of randomized controlled trials. Medicine. 2015;94:e1714
82. Agerholm-Larsen L, Bell ML, Grunwald GK, et al. The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies. Eur J Clin Nutr. 2000;54:856-860
83. Shimizu M, Hashiguchi M, Shiga T, et al. Meta-analysis: effects of probiotic supplementation on lipid profiles in normal tomildly hypercholesterolemic individuals. PLoS One. 2015;10:e0139795. doi:10.1371/journal.pone.0139795
84. Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis (Review). 2015;60(suppl 2):S129-S134
85. Ma J, Li Y, Ye Q, et al. Constituents of red yeast rice, a traditional Chinese food and medicine. J Agric Food Chem. 2000;48:5220-5225
86. Gordon RY, Cooperman T, Obermeyer W, et al. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med. 2010;170:1722-1727
87. Wang RW, Kari PH, Lu AY, et al. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys. 1991;290:355-361
88. Li YG, Zhang F, Wang ZT, et al. Identification and chemical profiling of monacolins in red yeast rice using high-performance liquid chromatography with photodiode array detector and mass spectrometry. J Pharm Biomed Anal. 2004;35:1101-1112
89. Gerards MC, Terlou RJ, Yu H, et al. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain-a systematic review and meta-analysis. Atherosclerosis. 2015;240:415-423
90. Mazzanti G, Moro PA, Raschi E, et al. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. Br J Clin Pharmacol. 2017;83:894-908
91. Liu J, Zhang J, Shi Y, et al. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 2006;1:4. doi:10.1186/1749-8546-1-4
92. Zhao SP, Liu L, Cheng YC, et al. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation. 2004;110:915-920
93. Kantola T, Kivistö KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1998;63:397-402
94. DFG Permanent Senate Commission on Food Safety. Toxicological Evaluation of Red Mould Rice: An update. Bonn, Germany: Deutsche Forschungsgemeinschaft; 2012
95. Prasad GV, Wong T, Meliton G, et al. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation. 2002;74:1200-1201
96. Rasheva TV, Nedeva TS, Hallet JN, et al. Characterization of a non-pigment producing Monascus purpureus mutant strain. Antonie Van Leeuwenhoek. 2003;83:333-340
97. Arai M, Hibino T. Tumorigenicity of citrinin in male F344 rats. Cancer Lett. 1983;17:281-287
98. Chan WH, Shiao NH. Effect of citrinin on mouse embryonic development in vitro and in vivo. Reprod Toxicol. 2007;24:120-5
99. Singh ND, Sharma AK, Dwivedi P, et al. Experimentally induced citrinin and endosulfan toxicity in pregnant Wistar rats: histopathological alterations in liver and kidneys of fetuses. J Appl Toxicol. 2008;28:901-907
100. EFSA Panel on Contaminants in the Food Chain (CONTAM), European Food Safety Authority (EFSA), Parma, Italy. Scientific opinion on the risks for public and animal health related to the presence of citrinin in food and feed. EFSA J. 2012;10:2605. doi:10.2903/j.efsa.2012.2605
101. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), European Food Safety Authority (EFSA), Parma, Italy. Scientific opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL-cholesterol concentrations (ID 1648, 1700) pursuant to article 13(1) of regulation (EC) no 1924/20061. EFSA J. 2011;9:2304. doi:10.2903/j.efsa.2011.2304
102. Borlinghaus J, Albrecht F, Grunhlke MCH, et al. Allicin: chemistry and biological properties. Molecules. 2014;19:12591-12618
103. Ried K, Toben C, Fakler P. Effect on garlic on serum lipids: an updated meta-analysis. Nutr Rev. 2013;71:282-299
104. Ackermann RT, Mulrow CD, Ramirez G, et al. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med. 2001;161:813-824
105. Ried K. Garlic lowers blood pressure in hypertensive individuals, regulates serum cholesterol, and stimulates immunity: an updated meta-analysis and review. J Nutr. 2016;146:389S-396S
106. Jung ES, Park SH, Choi EK, et al. Reduction of blood lipid parameters by a 12-wk supplementation of aged black garlic: a randomized controlled trila. Nutrition. 2014;30:1034-1039
107. Sahebkar A, Serban C, Ursoniu S, et al. Effect of garlic on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled clinical trials. Nutrition. 2016;32:33-40
108. Morihara N, Hino A. Aged garlic extract suppresses platelet aggregation by changing the functional property of platelets. J Nat Med. 2017;71:249-256
109. Cighetti G, Del Puppo M, Paroni R, et al. Modulation of HMG-CoA reductase activity by pantetheine/pantethine. Biochim Biophys Acta. 1988;963:389-393
110. Cighetti G, Del Puppo M, Paroni R, et al. Pantethine inhibits cholesterol and fatty acid syntheses and stimulates carbon dioxide formation in isolated rat hepatocytes. J Lipid Res. 1987;28:152-161
111. Eto M, Watanabe K, Chonan N, et al. Lowering effect of pantethine on plasma beta-thromboglobulin and lipids in diabetes mellitus. Artery. 1987;15:1-12
112. Binaghi P, Cellina G, Lo Cicero G, et al. Evaluation of the cholesterol-lowering effectiveness of pantethine in women in perimenopausal age. Minerva Med. 1990;81:475-479
113. Rumberger JA, Napolitano J, Azumano I, et al. Pantethine, a derivative of vitamin B(5) used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low-to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. Nutr Res. 2011;31:608-615
114. Evans M, Rumberger JA, Azumano I, et al. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation. Vasc Health Risk Manag. 2014;10:89-100
115. Bertolini S, Donati C, Elicio N, et al. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: adults and children. Int J Clin Pharmacol Ther Toxicol. 1986;24:630-637
116. Donati C, Barbi G, Cairo G, et al. Pantethine improves the lipid abnormalities of chronic hemodialysis patients: results of a multicenter clinical trial. Clin Nephrol. 1986;25:70-74
117. Giglio RV, Patti AM, Nikolic D, et al. The effect of bergamot on dyslipidemia. Phytomedicine. 2016;23:1175-1181
118. Di Donna L, De Luca G, Mazzotti F, et al. Statin-like principles of bergamot fruit (Citrus bergamia): isolation of 3-hydroxymethylglutaryl flavonoid glycosides. J Nat Prod. 2009;72:1352-1354
119. Miceli N, Mondello MR, Monforte MT, et al. Hypolipidemic effects of Citrus bergamia Risso et Poiteau juice in rats fed a hypercholesterolemic diet. J Agric Food Chem. 2007;55:10671-10677
120. Gliozzi M, Walker R, Muscoli S, et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Int J Cardiol. 2013;170:140-145
121. GliozziM, Carresi C, Musolino V, et al. The effect of bergamot-derived polyphenolic fraction on LDL small dense particles and non alcoholic fatty liver disease in patients with metabolic syndrome. Adv Biol Chem. 2014;4:129-137
122. Athyros VG, Tziomalos K, Katsiki N, et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World J Gastroenterol. 2015;21:6820-6834
123. Mollace V, Sacco I, Janda E, et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia. 2011;82:309-316
124. Chen JT, Wesley R, Shamburek RD, et al. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy. 2005;25:171-183
125. Singh DK, Li L, Porter TD. Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase. J Pharmacol Exp Ther. 2006;318:1020-1026
126. Berthold HK, Unverdorben S, Degenhardt R, et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA. 2006;295:2262-2269
127. Backes JM, Gibson CA, Ruisinger JF, et al. Modified-policosanol does not reduce plasma lipoproteins in hyperlipidemic patients when used alone or in combination with statin therapy. Lipids. 2011;46:923-929
128. Reiner Ź, Tedeschi-Reiner E, Romič Ź. Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients. Clin Drug Invest. 2005;25:701-707
129. Reiner Ź, Tedeschi-Reiner E. Rice policosanol does not have any effects on blood coagulation factors in hypercholesterolemic patients. Coll Antropol. 2007; 31:315-319
130. Liu CS, Zheng YR, Zhang YF, et al. Research progress on berberine with a special focus on its oral bioavailability. Fitoterapia. 2016;109:274-282
131. Abidi P, Zhou Y, Jiang JD, et al. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol. 2005;25:2170-2176
132. Li H, Dong B, Park SW, et al. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem. 2009;284:28885-28895
133. Li XY, Zhao ZX, Huang M, et al. Effect of berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. J Transl Med. 2015;13:278. doi:10.1186/s12967-015-0629-3
134. Qiang X, Xu L, Zhang M, et al. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. Biochem Biophys Res Commun. 2016;472:603-609
135. Kim WS, Lee YS, Cha SH, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab. 2009;296:E812-E819
136. Zarei A, Changizi-Ashtiyani S, Taheri S, et al. A quick overview on some aspects of endocrinological and therapeutic effects of Berberis vulgaris L. Avicenna J Phytomed. 2015;5:485-497
137. Meng S, Wang LS, Huang ZQ, et al. Berberine ameliorates inflammation in patients with acute coronary syndrome following percutaneous coronary intervention. Clin Exp Pharmacol Physiol. 2012;39:406-411
138. Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69-81
139. Derosa G, Maffioli P, Cicero AF. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther. 2012;12:1113-1124
140. Sosnowska B, Penson P, Banach M. The role of nutraceuticals in the prevention of cardiovascular disease. Cardiovasc Diagn Ther. 2017;7(suppl 1):S21-S31
141. Way TD, Lin HY, Kuo DH, et al. Pu-erh tea attenuates hyperlipogenesis and induces hepatoma cells growth arrest through activating AMP-activated protein kinase (AMPK) in human HepG2 cells. J Agric Food Chem. 2009;57:5257-5264
142. Shishikura Y, Khokhar S, Murray BS. Effects of tea polyphenols on emulsification of olive oil in a small intestine model system. J Agric Food Chem. 2006;54:1906-1913
143. Onakpoya I, Spencer E, Heneghan C, et al. The effect of green tea on blood pressure and lipid profile: a systematic review and meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis. 2014;24:823-836
144. Park CS, Kim W, Woo JS, et al. Green tea consumption improves endothelial function but not circulating endothelial progenitor cells in patients with chronic renal failure. Int J Cardiol. 2010;145:261-262
145. Lin QF, Qiu CS, Wang SL, et al. A cross-sectional study of the relationship between habitual tea consumption and arterial stiffness. J Am Coll Nutr. 2016;35:354-361
146. Serban C, Sahebkar A, Antal D, et al. Effects of supplementation with green tea catechins on plasma C-reactive protein concentrations: a systematic review and meta-analysis of randomized controlled trials. Nutrition. 2015;31:1061-1071
147. Zhang C, Qin YY, Wei X, et al. Tea consumption and risk of cardiovascular outcomes and total mortality: a systematic review and meta-analysis of prospective observational studies. Eur J Epidemiol. 2015;30:103-113
148. Cicero AF, Fogacci F, Colletti A. Potential role of bioactive peptides in prevention and treatment of chronic diseases: a narrative review. Br J Pharmacol. 2017;174:1378-1394
149. Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr. 2003;57:940-946
150. Cho SJ, Juillerat MA, Lee CH. Cholesterol loweringmechanism of soybean protein hydrolysate. J Agric Food Chem. 2007;55:10599-10604
151. Grieco A, Miele L, Pompili M, et al. Acute hepatitis caused by a natural lipidlowering product: when 'alternative' medicine is no 'alternative' at all. J Hepatol. 2009;50:1273-1277
152. Potter SM. Overview of proposed mechanisms for the hypocholesterolemic effect of soy. J Nutr. 1995;125(3 suppl):606S-611S
153. Lammi C, Zanoni C, Scigliuolo GM, et al. Lupin peptides lower low-density lipoprotein (LDL) cholesterol through an up-regulation of the LDL receptor/sterol regulatory element binding protein 2 (SREBP2) pathway at HepG2 cell line. J Agric Food Chem. 2014;62:7151-7159
154. Tokede OA, Onabanjo TA, Yansane A, et al. Soya products and serum lipids: a meta-analysis of randomised controlled trials. Br J Nutr. 2015;114:831-843
155. Beavers DP, Beavers KM, Miller M, et al. Exposure to isoflavone-containing soy products and endothelial function: a Bayesian meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2012;22:182-191
156. Hazim S, Curtis PJ, Schär MY, et al. Acute benefits of the microbial-derived isoflavone metabolite equol on arterial stiffness in men prospectively recruited according to equol producer phenotype: a double-blind randomized controlled trial. Am J Clin Nutr. 2016;103:694-702
157. Arnoldi A, Greco S. Nutraceutical characteristics of lupin protein. Nutrafoods. 2011;10:23-29
158. Bähr M, Fechner A, Krämer J, et al. Lupin protein positively affects plasma LDL cholesterol and LDL:HDL cholesterol ratio in hypercholesterolemic adults after four weeks of supplementation: a randomized, controlled crossover study. Nutr J. 2013;12:107. doi:10.1186/1475-2891-12-107
159. Bähr M, Fechner A, Kiehntopf M, et al. Consuming a mixed diet enriched with lupin protein beneficially affects plasma lipids in hypercholesterolemic subjects: a randomized controlled trial. Clin Nutr. 2015;34:7-14
160. Fechner A, Kiehntopf M, Jahreis G. The formation of short-chain fatty acids is positively associated with the blood lipid-lowering effect of lupin kernel fiber in moderately hypercholesterolemic adults. J Nutr. 2014;144:599-607
161. EFSA Panel on Dietetic Products, Nutrition, and Allergies. Scientific opinion on the substantiation of health claims related to EPA, DHA, DPA and maintenance of normal blood pressure (ID 502), maintenance of normal HDL-cholesterol concentrations (ID 515), maintenance of normal (fasting) blood concentrations of triglycerides (ID 517), maintenance of normal LDL-cholesterol concentrations (ID 528, 698) and maintenance of joints (ID 503, 505, 507, 511, 518, 524, 526, 535, 537) pursuant to article 13(1) of regulation (EC) no 1924/2006. EFSA J. 2009;7:1263-1289
162. EFSA Panel on Dietetic Products, Nutrition, and Allergies. Scientific opinion on the substantiation of health claims related to eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and maintenance of normal cardiac function (ID 504, 506, 516, 527, 538, 703, 1128, 1317, 1324, 1325), maintenance of normal blood glucose concentrations (ID 566), maintenance of normal blood pressure (ID 506, 516, 703, 1317, 1324), maintenance of normal blood HDL-cholesterol concentrations (ID 506), maintenance of normal (fasting) blood concentrations of triglycerides (ID 506, 527, 538, 1317, 1324, 1325), maintenance of normal blood LDL-cholesterol concentrations (ID 527, 538, 1317, 1325, 4689), protection of the skin from photo-oxidative (UV-induced) damage (ID 530), improved absorption of EPA and DHA (ID 522, 523), contribution to the normal function of the immune system by decreasing the levels of eicosanoids, arachidonic acid-derived mediators and pro-inflammatory cytokines (ID 520, 2914), and 'immunomodulating agent' (4690) pursuant to article 13(1) of regulation (EC) no 1924/20061. EFSA J. 2010;8:1796-1828
163. Howe P, Mori T, Buckley J. Long Chain Omega-3 Fatty Acids and Cardiovascular Disease-FSANZ Consideration of a Commissioned Review. http://www.food standards.gov.au/consumer/labelling/nutrition/documents/FSANZ%20consider ation%20of%20omega-3%20review1.pdf. Accessed March 31, 2017
164. Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292-2333
165. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol. 2006;17:387-393
166. Eslick GD, Howe PR, Smith C, et al. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol. 2009;136:4-16
167. Leslie MA, Cohen DJ, Liddle DM, et al. A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals. Lipids Health Dis. 2015;14:53. doi:10.1186/s12944-015-0049-7
168. Di Stasi D, Bernasconi R, Marchioli R, et al. Early modifications of fatty acid composition in plasma phospholipids, platelets and mononucleates of healthy volunteers after low doses of n-3 polyunsaturated fatty acids. Eur J Clin Pharmacol. 2004;60:183-190
169. Trumbo P, Schlicker S, Yates AA, et al. Food and Nutrition Board of the Institute of Medicine, The National Academies. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. J Am Diet Assoc. 2002;102:1621-1630
170. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13:474-483
171. Cicero AF, Reggi A, Parini A, et al. Application of polyunsaturated fatty acids in internal medicine: beyond the established cardiovascular effects. Arch Med Sci. 2012;8:784-793
172. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto miocardico (GISSI). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 199;354:447-455
173. Cicero AF, Colletti A. Krill oil: evidence of a new source of polyunsaturated fatty acids with high bioavailability. Clin Lipidol. 2015;10:1-4
174. Ulven SM, Kirkhus B, Lamglait A, et al. Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers. Lipids. 2011;46:37-46
175. Cicero AF, Rosticci M, Morbini M, et al. Lipid-lowering and anti-inflammatory effects of omega 3 ethyl esters and krill oil: a randomized, cross-over, clinical trial. Arch Med Sci. 2016;12:507-512
176. Ursoniu S, Sahebkar A, Serban MC, et al. Lipid and Blood Pressure Meta-analysis Collaboration Group. Lipid-modifying effects of krill oil in humans: systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2017;75:361-373
177. Pan A, Yu D, Demark-Wahnefried W, et al. Meta-analysis of the effects of flexseed interventions on blood lipids. Am J Clin Nutr. 2009;90:288-297
178. Ursoniu S, Sahebkar A, Andrica F, et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Effects of flaxseed supplements on blood pressure: a systematic review and meta-analysis of controlled clinical trial. Clin Nutr. 2016;35:615-625
179. Khalesi S, Paukste E, Nikbakht E, et al. Sesame fractions and lipid profiles: a systematic review and meta-analysis of controlled trials. Br J Nutr. 2016;115:764-773
180. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015-2026
181. Kotwal S, Jun M, Sullivan D, et al. Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012;5:808-818
182. Cicero AF, Gaddi A. Rice bran oil and gamma-oryzanol in the treatment of hyperlipoproteinaemias and other conditions. Phytother Res. 2001;15:277-289
183. Mäkynen K, Chitchumroonchokchai C, Adisakwattana S, et al. Effect of gammaoryzanol on the bioaccessibility and synthesis of cholesterol. Eur Rev Med Pharmacol Sci. 2012;16:49-56
184. Kim HW, Kim JB, Cho SM, et al. Characterization and quantification of c-oryzanol in grains of 16 Korean rice varieties. Int J Food Sci Nutr. 2015;66:166-174
185. Jolfaie NR, Rouhani MH, Surkan PJ, et al. Rice bran oil decreases total and LDL cholesterol in humans: a systematic review and meta-analysis of randomized controlled clinical trials. Horm Metab Res. 2016;48:417-426
186. Nagaoka S, Shimizu K, Kaneko H, et al. A novel protein C-phycocyanin plays a crucial role in the hypocholesterolemic action of spirulina platensis concentrate in rats. J Nutr. 2005;135:2425-2430
187. Serban MC, Sahebkar A, Dragan S, et al. A systematic review and meta-analysis of the impact of spirulina supplementation on plasma lipid concentrations. Clin Nutr. 2016;35:842-851
188. Pulido-Moran M, Moreno-Fernandez J, Ramirez-Tortosa C, et al. Curcumin and health. Molecules. 2016;21:264. doi:10.3390/molecules21030264
189. Panahi Y, Hosseini MS, Khalili N, et al. Effects of supplementation with curcumin on serum adipokine concentrations: a randomized controlled trial. Nutrition. 2016;32:1116-1122
190. Sahebkar A, Cicero AF, Simental-Mendĭa LE, et al. Curcumin downregulates human tumor necrosis factor-a levels: a systematic review and meta-analysis ofrandomized controlled trials. Pharmacol Res. 2016;107:234-242
191. Kumar P, Malhotra P, Ma K, et al. SREBP2 mediates the modulation of intestinal NPC1L1 expression by curcumin. Am J Physiol Gastrointest Liver Physiol. 2011;301:G148-G155
192. Liu XL, Liu MH, Hu HJ, et al. Curcumin enhanced choelsterol efflux by upregulating ABCA1 expression through AMPK-SIRT1-LXRalpha signaling in THP-1 macrophage-derived foam cells. DNA Cell Biol. 2015;34:561-572
193. Tai MH, Chen PK, Chen PY, et al. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells. Mol Nutr Food Res. 2014;58:2133-2145
194. Momtazi AA, Derosa G, Maffioli P, et al. Role of microRNAs in the therapeutic effects of curcumin in non-cancer diseases. Mol Diagn Ther. 2016;20:335-345
195. Sahebkar A. A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels. Clin Nutr. 2014;33:406-414
196. Yang YS, Su YF, Yang HW, et al. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2014;28:1770-1777
197. Panahi Y, Khalili N, Hosseini MS, et al. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med. 2014;22:851-857
198. Rahmani S, Asgary S, Askari G, et al. Treatment of non-alcoholic fatty liver disease with curcumin: a randomized placebo-controlled trial. Phytother Res. 2016;30:1540-1548
199. Panahi Y, Kianpour P, Mohtashami R, et al. Curcumin lowers serum lipids and uric acid in subjects with non-alcoholic fatty liver disease: a randomized controlled trial. J Cardiovasc Pharmacol. 2016;68:223-229
200. Derosa G, Limas CP, Macĭas PC, et al. Dietary and nutraceutical approach to type 2 diabetes. Arch Med Sci. 2014;10:336-344
201. Nakayama H, Tsuge N, Sawada H, et al. A single consumption of curry improved postprandial endothelial function in healthy male subjects: a randomized, controlled crossover trial. Nutr J. 2014;13:67. doi:10.1186/1475-2891-13-67
202. Chuengsamarn S, Rattanamongkolgul S, Phonrat B, et al. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem. 2014;25:144-150
203. Rahimi HR, Nedaeinia R, Sepehri Shamloo A, et al. Novel delivery system for natural products: nano-curcumin formulations. Avicenna J Phytomed. 2016;6:383-398
204. El-Hattab AW, Scaglia F. Disorders of carnitine biosynthesis and transport. Mol Genet Metab. 2015;116:107-112
205. Serban MC, Sahebkar A, Mikhailidis DP, et al. Impact of L-carnitine on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of randomized controlled trials. Sci Rep. 2016;6:19188. doi:10.1038/srep19188
206. Pooyandjoo M, Nouhi M, Shab-Bidar S, et al. The effect of (L-) carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2016;17:970-976
207. Mazidi M, Rezaie P, Banach M. Impact of L-carnitine on C-reactive protein. A systematic review and meta-analysis of 10 randomized control trials with 925 patients. Paper presented at: 2nd CPPEI Congress; July 2017; Vienna, Austria
208. Capasso F, Gaginella TS, Grandolini G, et al. Phytotherapy: A Quick Reference to Herbal Medicine. Berlin, Germany: Springer; 2003
209. Safaa M, Hanaa A, Abdel F, et al. Cynara scolymus for relieving on nonalcoholic steatohepatitis induced in rat. Int J Pharm Pharmac Sci. 2013;5:57-66
210. Rangboo V, Noroozi M, Zavoshy R, et al. The effect of artichoke leaf extract on alanine aminotransferase and aspartate aminotransferase in the patients with nonalcoholic steatohepatitis. Int J Hepatol. 2016;2016:4030476. doi:10.1155/2016/4030476
211. Bundy R, Walker AF, Middleton RW, et al. Artichoke leaf extract (Cynara scolymus) reduces plasma cholesterol in otherwise healthy hypercholesterolemic adults: a randomized, double blind placebo controlled trial. Phytomedicine. 2008;15:668-675
212. Englisch W, Beckers C, Unkauf M, et al. Efficacy of artichoke dry extract in patients with hyperlipoproteinemia. Arzneimittelforschung. 2000;50:260-265
213. Petrowicz O, Gebhardt R, Donner M, et al. Effects of artichoke leaf extract (ALE) on lipoprotein metabolismin vitro and in vivo. Atherosclerosis. 1997;129:147
214. Sahebkar A, Pirro M, Banach M, et al. Lipid-lowering activity of artichoke extracts: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2017; Advance Access published June 13, doi:10.1080/10408398.2017.1332572
215. Li F, Tan W, Kang Z, et al. Tocotrienol enriched palm oil prevents atherosclerosis through modulating the activities of peroxisome proliferators-activated receptors. Atherosclerosis. 2010;211:278-282
216. Ajuluchukwu JN, Okubadejo NU, Mabayoje M, et al. Comparative study of the effect of tocotrienols and-tocopherol on fasting serum lipid profiles in patients with mild hypercholesterolaemia: a preliminary report. Niger Postgrad Med J. 2007;14:30-33
217. Rasool AH, Rahman AR, Yuen KH, et al. Arterial compliance and vitamin E blood levels with a self emulsifying preparation of tocotrienol rich vitamin E. Arch Pharm Res. 2008;31:1212-1217
218. Prasad K. Tocotrienols and cardiovascular health. Curr Pharm Des. 2011;17:2147-2154
219. Loffredo L, Perri L, Di Castelnuovo A, et al. Supplementation with vitamin E alone is associated with reduced myocardial infarction: a meta-analysis. Nutr Metab Cardiovasc Dis. 2015;25:354-363
220. Sen CK, Khanna S, Rink C, et al. Tocotrienols: the emerging face of natural vitamin E. Vitam Horm. 2007;76:203-261
221. Wallace TC, Slavin M, Frankenfeld CL. Systematic review of anthocyanins and markers of cardiovascular disease. Nutrients. 2016;8:pii:E32. doi:10.3390/nu8010032
222. Li D, Zhang Y, Liu Y, et al. Purified anthocyanin supplementation reduces dyslipidemia, enhances antioxidant capacity, and prevents insulin resistance in diabetic patients. J Nutr. 2015;145:742-748
223. Davinelli S, Bertoglio JC, Zarrelli A, et al. A randomized clinical trial evaluating the efficacy of an anthocyanin-maqui berry extract (DelphinolVR) on oxidative stress biomarkers. J Am Coll Nutr. 2015;34(suppl 1):28-33
224. Jennings A, Welch AA, Fairweather-Tait SJ, et al. Higher anthocyanin intake is associated with lower arterial stiffness and central blood pressure in women. Am J Clin Nutr. 2012;96:781-788
225. Marques C, Fernandes I, Norberto S, et al. Pharmacokinetics of blackberry anthocyanins consumed with or without ethanol: a randomized and crossover trial. Nutr Food Res. 2016;60:2319-2330
226. Skottovă N, Krecman V. Silymarin as a potential hypocholesterolaemic drug. Physiol Res. 1998;47:1-7
227. Voroneanu L, Nistor I, Dumea R, et al. Silymarin in type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. J Diabetes Res. 2016;2016:5147468. doi:10.1155/2016/5147468
228. Mitchell PL, McLeod RS. Conjugated linoleic acid and atherosclerosis: studies in animal models. Biochem Cell Biol. 2008;86:293-301
229. Farvid MS, Ding M, Pan A, et al. Dietary linoleic acid and risk of coronary heart disease: a systematic review and meta-analysis of prospective cohort studies. Circulation. 2014;130:1568-1578
230. Derakhshande-Rishehri SM, Mansourian M, Kelishadi R, et al. Association of foods enriched in conjugated linoleic acid (CLA) and CLA supplements with lipid profile in human studies: a systematic review and meta-analysis. Public Health Nutr. 2015;18:2041-2054
231. Taylor JS, Williams SR, Rhys R, et al. Conjugated linoleic acid impairs endothelial function. Arterioscler Thromb Vasc Biol. 2006;26:307-312
232. Sahebkar A, Serban C, Ursoniu S, et al. Lipid and Blood Pressure Meta-analysis Collaboration Group. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors-results from a systematic review and metaanalysis of randomized controlled trials. Int J Cardiol. 2015;189:47-55
233. Aziz Z, Wong SY, Chong NJ. Effects of Hibuscus sabdariffa L. on serum lipids: a systematic review and meta-analysis and meta-analysis. J Ethnopharmacol. 2013;150:442-450
234. Serban C, Sahebkar A, Ursoniu S, et al. Effect of sour tea (Hibiscus sabdariffa L.) on arterial hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2015;33:1119-1127
235. Ursoniu S, Sahebkar A, Serban MC, et al. Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials. Arch Med Sci. 2015;11:253-266
236. Cicero AF, Colletti A. Combinations of phytomedicines with different lipid lowering activity for dyslipidemia management: the available clinical data. Phytomedicine. 2016; 23:1113-1118
237. Cicero AF, Ferroni A, Ertek S. Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects. Expert Opin Drug Saf. 2012;11:753-766
238. Cicero AF, Parini A, Rosticci M. Nutraceuticals and cholesterol-lowering action. Int J Cardiol Med Endocr. 2015;6:1-4
239. Cicero AF, Brancaleoni M, Laghi L, et al. Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: a pilot study. Complement Ther Med. 2005;13:273-278
240. Stefanutti C, Mazza F, Vivenzio A, et al. Combined treatment with Dif1stat and diet reduce plasma lipid indicators of moderate hypercholesterolemia more effectively than diet alone: a randomized trial in parallel groups. Lipids. 2009;44:1141-1148
241. Cicero AF, Benvenuti C; ARMoweb study Group. Efficacy of a red yeast rice based nutraceutical in large subgroups of hypercholesterolemic subjects in every day clinical practice. Med J Nutr Metab. 2010;3:239-246
242. Guardamagna O, Abello F, Baracco V, et al. The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis. 2011;21:424-429
243. Pirro M, Mannarino MR, Bianconi V, et al. The effects of a nutraceutical combination on plasma lipids and glucose: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2016;110:76-88
244. Pirro M, Mannarino MR, Ministrini S, et al. Effects of a nutraceutical combination on lipids, inflammation and endothelial integrity in patients with subclinical inflammation: a randomized clinical trial. Sci Rep. 2016;6:23587
245. Marazzi G, Cacciotti L, Pelliccia F, et al. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther. 2011;28:1105-1113
246. Cicero AF, Derosa G, Borghi C. Red yeast rice and statin-intolerant patients. Am J Cardiol. 2010;105:1504
247. De Castro-Orǒs I, Solă R, Valls RM, et al. Genetic variants of LDLR and PCSK9 associated with variations in response to antihypercholesterolemic effects of armolipid plus with berberine. PLoS One. 2016;11:e0150785. doi:10.1371/journal.pone.0150785
248. Affuso F, Ruvolo A, Micillo F, et al. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis. 2010;20:656-661
249. Cicero AF, Parini A, Rosticci M, et al. Effect of a lipid-lowering nutraceutical on pulse-wave-velocity in hypercholesterolemic patients with or without chronic kidney disease. Open Hypertension J. 2013;5:18-22
250. Kamal-Eldin A, Moazzami A. Plant sterols and stanols as cholesterol-lowering ingredients in functional foods. Recent Pat Food Nutr Agric. 2009;1:1-14
251. Feuerstein JS, Bjerke WS. Powdered red yeast rice and plant stanols and sterols to lower cholesterol. J Diet Suppl. 2012;9:110-115
252. Cicero AF, Fogacci F, Rosticci M, et al. Effect of a short-term dietary supplementation with phytosterols, red yeast rice or both on lipid pattern in moderately hypercholesterolemic subjects: a three-arm, double-blind, randomized clinical trial. Nutr Metab 2017 (In press)
253. Ogier N, Amiot MJ, Georgé S, et al. LDL-cholesterol-lowering effect of a dietary supplement with plant extracts in subjects with moderate hypercholesterolemia. Eur J Nutr. 2013;52:547-557
254. Barrat E, Zaïr Y, Ogier N, et al. A combined natural supplement lowers LDL cholesterol in subjects with moderate untreated hypercholesterolemia: a randomized placebo-controlled trial. Int J Food Sci Nutr. 2013;64:882-889
255. Barrat E, Zaïr Y, Sirvent P, et al. Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study. Eur J Nutr. 2013;52:1843-1852
256. Cicero AF, Colletti A, Fogacci F, et al. Effects of a combined nutraceutical on lipid pattern, glucose metabolism and inflammatory parameters in moderately hypercholesterolemic subjects: a double-blind, cross-over, randomized clinical trial. High Blood Press Cardiovasc Prev. 2016;24:13-18
257. Derosa G, Bonaventura A, Bianchi L, et al. A randomized, placebo-controlled study on the effects of a nutraceutical combination of red yeast rice, silybum marianum and octasonol on lipid profile, endothelial and inflammatory parameters. J Biol Regul Homeost Agents. 2014;28:317-324
258. Cicero AF, Colletti A, Rosticci M, et al. Efficacy and tolerability of a combined lipid-lowering nutraceutical on cholesterolemia, hs-CRP level and endothelial function in moderately hypercholesterolemic subjects. J Biol Regul Homeost Agents. 2016;30:593-598
259. Cicero AF, Derosa G, Parini A, et al. Red yeast rice improves lipid pattern, highsensitivity C-reactive protein, and vascular remodeling parameters in moderately hypercholesterolemic Italian subjects. Nutr Res. 2013;33:622-628
260. Cicero AF, Morbini M, Rosticci M, et al. Middle-term dietary supplementation with red yeast rice plus coenzyme Q10 improves lipid pattern, endothelial reactivity and arterial stiffness in moderately hypercholesterolemic subjects. Ann Nutr Metab. 2016;68:213-219
261. Cicero AF, Morbini M, Parini A, et al. Effect of red yeast rice combined with antioxidants on lipid pattern, hs-CRP level, and endothelial function in moderately hypercholesterolemic subjects. Ther Clin Risk Manag. 2016;12:281-286
262. Cicero AF, Rosticci M, Parini A, et al. Short-term effects of a combined nutraceutical of insulin-sensitivity, lipid level and indexes of liver steatosis: a double-blind, randomized, cross-over clinical trial. Nutr J. 2015;14:30
263. Derosa G, Bonaventura A, Bianchi L, et al. Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. Expert Opin Biol Ther. 2013;13:1495-1506
264. Cicero AF, Fiorito A, Panourgia MP, et al. Effects of a new soy/beta-sitosterol supplement on plasma lipids in moderately hypercholesterolemic subjects. J Am Diet Assoc. 2002;102:1807-1811
265. Lerman RH, Minich DM, Darland G, et al. Subjects with elevated LDL cholesterol and metabolic syndrome benefit from supplementation with soy protein, phytosterols, hops rho iso-alpha acids, and Acacia nilotica proanthocyanidins. J Clin Lipidol. 2010;4:59-68
266. Jenkins DJ, Kendall CW, Marchie A, et al. The effect of combining plant sterols, soy protein, viscous fibers, and almonds in treating hypercholesterolemia. Metabolism. 2003;52:1478-1483
267. Cicero AF, Derosa G, Pisciotta L, et al. SISA-PUFACOL Study Group. Testing the short-term efficacy of a lipid-lowering nutraceutical in the setting of clinical practice: a multicenter study. J Med Food. 2015;18:1270-1273
268. Lee IT, Lee WJ, Tsai CM, et al. Combined extractives of red yeast rice, bitter gourd, chlorella, soy protein, and licorice improve total cholesterol, low-density lipoprotein cholesterol, and triglyceride in subjects with metabolic syndrome. Nutr Res. 2012;32:85-92
269. Shrestha S, Volek JS, Udani J, et al. A combination therapy including psyllium and plant sterols lowers LDL cholesterol by modifying lipoprotein metabolism in hypercholesterolemic individuals. J Nutr. 2006;136:2492-2497
270. Micallef MA, Garg ML. The lipid-lowering effects of phytosterols and (n-3) polyunsaturated fatty acids are synergistic and complementary in hyperlipidemic men and women. J Nutr. 2008;138:1085-1090
271. Jeyaraj S, Shivaji G, Jeyaraj SD, et al. Effect of combined supplementation of fish oil with garlic pearls on the serum lipid profile in hypercholesterolemic subjects. Indian Heart J. 2005;57:327-331
272. Accinni R, Rosina M, Bamonti F, et al. Effects of combined dietary supplementation on oxidative and inflammatory status in dyslipidemic subjects. Nutr Metab Cardiovasc Dis. 2006;16:121-127
273. Sirtori CR, Triolo M, Bosisio R, et al. Hypocholesterolaemic effects of lupin protein and pea protein/fibre combinations in moderately hypercholesterolaemic individuals. Br J Nutr. 2012;107:1176-1183
274. Yoshida M, Vanstone CA, Parsons WD, et al. Effect of plant sterols and glucomannan on lipids in individuals with and without type II diabetes. Eur J Clin Nutr. 2006;60:529-537
275. Houston M, Sparks W. Effect of combination pantethine, plant sterols, green tea extract, delta-tocotrienol and phytolens on lipid profiles in patients with hyperlipidemia. JANA. 2010;13:15-20
276. Sabatine MS. Advances in the treatment of dyslipidemia. Cleve Clin J Med. 2016;83:181-186
277. Śimič I, Reiner Ź. Adverse effects of statins-myths and reality. Curr Pharm Des. 2015;21:1220-1226
278. Banach M, Stulc T, Dent R, et al. Statin non-adherence and residual cardiovascular risk: there is need for substantial improvement. Int J Cardiol. 2016;225:184-196
279. Reiner Ź. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol. 2010;24:19-28
280. Cicero AF, Morbini M, Bove M, et al. Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic. Curr Med Res Opin. 2016:2016;1-6
281. Cicero AF, Colletti A. Statins and nutraceuticals/functional food: could they be combined? In Banach M, ed. Combination Therapy in Dyslipidemia. Heidelberg, Germany: Springer International Publishing; 2016:127-142
282. Maki KC, OrloffDG, Nicholls SJ, et al. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statintreated patients with residual hypertriglyceridemia (the ESPRIT trial). Clin Ther. 2013;35:1400-1411.e1-3
283. Kim SH, Kim MK, Lee HY, et al. Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profiles and heart rate variability. Eur J Clin Nutr. 2011;65:110-116
284. Yokoyama M, Origasa H, Matsuzaki M, et al. Japan EPA lipid intervention study (JELIS) investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090-1098
285. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354:447-455
286. Agrawal AR, Tandon M, Sharma PL. Effect of combining viscous fibre with lovastatin on serum lipids in normal human subjects. Int J Clin Pract. 2007;61:1812-1818
287. Moreyra AE, Wilson AC, Koraym A. Effect of combining psyllium fiber with simvastatin in lowering cholesterol. Arch Intern Med. 2005;165:1161-1166
288. Ramos SC, Fonseca FA, Kasmas SH, et al. The role of soluble fiber intake in patients under highly effective lipid-lowering therapy. Nutr J. 2011;10:80. doi:10.1186/1475-2891-10-80
289. Marazzi G, Pelliccia F, Campolongo G, et al. Usefulness of nutraceuticals (Armolipid Plus) versus ezetimibe and combination in statin-intolerant patients with dyslipidemia with coronary heart disease. Am J Cardiol. 2015;116:1798-1801
290. Pisciotta L, Bellocchio A, Bertolini S. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Lipids Health Dis. 2012;11:123. doi:10.1186/1476-511X-11-123
291. Di Pierro F, Bellone I, Rapacioli G, et al. Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins. Diabetes Metab Syndr Obes. 2015;8:89-96
292. Malina DM, Fonseca FA, Barbosa SA, et al. Additive effects of plant sterols supplementation in addition to different lipid-lowering regimens. J Clin Lipidol. 2015;9:542-552
293. Gylling H, Miettinen TA. LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects. Nutr Metab Cardiovasc Dis. 2002;12:19-23
294. Qureshi AA, Sami SA, Salser WA, et al. Synergistic effect of tocotrienol-rich fraction (TRF 25) of rice bran and lovastatin on lipid parameters in hypercholesterolemic humans. J Nutr Biochem. 2001;12:318-329
295. Ahmad Alobaidi AH. Effect of Nigella sativa and Allium sativum coadminstered with simvastatin in dyslipidemia patients: a prospective, randomized, doubleblind trial. Antiinflamm Antiallergy Agents Med Chem. 2014;13:68-74
296. Qin XF, Zhao LS, Chen WR, et al. Effects of vitamin D on plasma lipid profiles in statin-treated patients with hypercholesterolemia: a randomized placebocontrolled trial. Clin Nutr. 2015;34:201-206
297. Michalska-Kasiczak M, Sahebkar A, Mikhailidis DP, et al. Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Analysis of vitamin D levels in patients with and without statin-associated myalgia-a systematic review and meta-analysis of 7 studies with 2420 patients. Int J Cardiol. 2015;178:111-116
298. Serban MC, Colantonio LD, Manthripragada AD, et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69:1386-1395